Clinical TrialJun 1, 2026, 04:56 PM
Greenwich LifeSciences Advances Phase III Trial; Corrects Prior Financials
AI Summary
Greenwich LifeSciences, Inc. is advancing its Phase III clinical trial, Flamingo-01, for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences, with enrollment ongoing in the US and Europe. The company reported promising Phase IIb results, showing an 80-100% reduction in recurrences for HER2/neu 3+ patients, despite noting some inconsistencies in the underlying data. The company also disclosed that its financial statements reflect the correction of an error to previously issued statements and highlighted its status as a non-accelerated and smaller reporting company, with a market value of approximately $56 million.
Key Highlights
- Phase III clinical trial (Flamingo-01) for GLSI-100 is actively enrolling patients in the US and Europe.
- Phase IIb trial data indicated an 80-100% reduction in breast cancer recurrences in HER2/neu 3+ patients.
- Financial statements reflect the correction of an error to previously issued financial statements.
- Company is classified as a non-accelerated filer and a smaller reporting company.
- Aggregate market value of non-affiliate common equity was approximately $56 million as of June 30, 2025.
- 14,678,208 shares of common stock were issued and outstanding as of May 26, 2026.
- Company anticipates continued substantial losses and requires significant additional financing.
- Relies on third-party manufacturers for product candidates and a single supplier for GM-CSF.
Price Impact
More from GLSI